Evaluation of the performance of a new automated HIV combination assay

In 1997, combination assays, termed “fourth-generation” EIAs, which detect both HIV-1 p24 antigen (Ag) and antibodies (Ab), became available in Europe, allowing the detection of early as well as established infections [1]. Since this time, more than 10 different fourth-generation assays have been licensed in Europe. These combinat ion assays reduce the seroconversion window period by 4–8days when compared to third generation EIAs, which only detect HIV antibodies [2,3]. European legislation requires that commercially available assays now need to detect both HIV-1 p24 antigen and HIV-1 and HIV-2 antibodies, with sensitivity for detection of p24 antigen of

Source: Journal of Clinical Virology - September 21, 2017 Category: Virology Authors: Valeria Ghisetti, Catherine Coignard, Tiziano Allice, Ly Thoai Duong Tags: Full length article Source Type: research